<DOC>
	<DOCNO>NCT01881425</DOCNO>
	<brief_summary>Assess safety effectiveness InnFocus MicroShunt use low intraocular pressure ( IOP ) subject primary open angle glaucoma IOP control use maximum tolerate glaucoma medication .</brief_summary>
	<brief_title>InnFocus MicroShunt Versus Trabeculectomy Study</brief_title>
	<detailed_description>This clinical trial prospective , randomize , control , multicenter , study . After informed consent obtain , patient evaluate eligibility base glaucoma severity , eye health , visual acuity . Clinical follow schedule course 24 month study , examination repeat monitor eye health . At 1 2 year follow , diurnal ( IOP take morning , mid-day , afternoon day ) IOP evaluation do . Annual follow occur 2 year . The primary effectiveness endpoint 20 % great reduction IOP pre-op medicate IOP 12 month .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<criteria>POAG maximum tolerate glaucoma med Medicated ≥15mmHg ≤40mmHg Previous conjunctival incisional ophthalmic surgery Anticipated need additional ocular surgery study Secondary glaucoma Any condition prevents device implantation trabeculectomy superior region study eye</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>POAG</keyword>
</DOC>